Market
Highest revenue growth in oncology treatments by end of 2025?
2
Resolution / Starting Odds
Johnson & Johnson • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Financial reports and revenue data from major pharmaceutical companies
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
More than 15% increase • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
North America • 25%
Asia-Pacific • 25%
Other • 25%
Europe • 25%
Other • 25%
AstraZeneca • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Breast Cancer • 25%
Gastrointestinal Cancer • 25%
Lung Cancer • 25%
Casgevy leads • 33%
BEAM-101 leads • 33%
Reni-cel leads • 33%
Roche • 25%
AstraZeneca • 25%
Daiichi Sankyo • 25%
Pfizer • 25%
No • 50%
Yes • 50%
Sub-Saharan Africa • 25%
Latin America • 25%
Southeast Asia • 25%
South Asia • 25%
Focus on internal development • 25%
Other strategic move • 25%
Another acquisition in oncology • 25%
Partnership with another biotech • 25%
Competitor drug leads market • 25%
No clear market leader • 25%
Other • 25%
LEQEMBI leads market • 25%
Another competitor • 34%
Eli Lilly • 33%
Novo Nordisk • 33%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
AstraZeneca • 25%